ArticleBiomarker research2018
Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study.
Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Multiplexed Remote SPR Detection of Biological Interactions through Optical Fiber Bundles.Sensors (Basel, Switzerland) · 2020Article
- Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.Cell reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundAcute kidney injury (AKI) is a frequent complication of cardiac surgery. We sought prognostic combinations of postoperative biomarkers measured within 6 h of surgery, potentially in combination with cardiopulmonary bypass time (to account for the degree of insult to the kidney). We used data from a large cohort of patients and adapted methods for developing biomarker combinations to account for the multicenter design of the study.
methodsThe primary endpoint was sustained mild AKI, defined as an increase of 50% or more in serum creatinine over preoperative levels lasting at least 2 days during the hospital stay. Severe AKI (secondary endpoint) was defined as a serum creatinine increase of 100% or more or dialysis during hospitalization. Data were from a cohort of 1219 adults undergoing cardiac surgery at 6 medical centers; among these, 117 developed sustained mild AKI and 60 developed severe AKI. We considered cardiopulmonary bypass time and 22 biomarkers as candidate predictors. We adapted Bayesian model averaging methods to develop center-adjusted combinations for sustained mild AKI by (1) maximizing the posterior model probability and (2) retaining predictors with posterior variable probabilities above 0.5. We used resampling-based methods to avoid optimistic bias in evaluating the biomarker combinations.
resultsThe maximum posterior model probability combination included plasma N-terminal-pro-B-type natriuretic peptide, plasma heart-type fatty acid binding protein, and change in serum creatinine from before to 0-6 h after surgery; the median probability combination additionally included plasma interleukin-6. The center-adjusted, optimism-corrected AUCs for these combinations were 0.80 (95% CI: 0.78, 0.87) and 0.81 (0.78, 0.87), respectively, for predicting sustained mild AKI, and 0.81 (0.76, 0.90) and 0.83 (0.76, 0.90), respectively, for predicting severe AKI. For these data, the Bayesian model averaging methods yielded combinations with prognostic capacity comparable to that achieved by standard frequentist methods but with more parsimonious models.
conclusionsPending external validation, the identified combinations could be used to identify individuals at high risk of AKI immediately after cardiac surgery and could facilitate clinical trials of renoprotective agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.